aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent covering methods for the use of anti-neuropilin-2 (NRP2) antibodies. The patent application No. 16/376,979 titled, “Compositions and methods comprising anti-NRP2 antibodies,” covers the use of a series of antibodies targeting NRP2 for differentiated therapeutic applications in the areas of cancer and inflammation.
NRP2 is a cell surface receptor that plays multiple roles in neurodevelopment, maintaining cellular plasticity, cell migration, lymphatic development and regulating inflammatory responses in normal physiology. The blocking antibodies that aTyr has developed target distinct domains of NRP2, including those interacting with semaphorins, VEGF and certain chemokines.
https://finance.yahoo.com/news/atyr-pharma-announces-notice-allowance-120000872.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.